Security key
432705309
Canton Strategic Holdings, Inc. - Common Stock (CNTN)
CUSIP: 432705309
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 24,257
- Total 13F value
- $60,157
- Share change
- +18,076
- SEC-reported price per share
- $2.46
- Number of holders
- 4
- Value change
- +$39,400
- Number of buys
- 2
- Number of sells
- 2
- Shares outstanding
- 80,321,350
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
4
Top holders
4
CNTN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Canton Strategic Holdings, Inc. SEC filings
Canton Strategic Holdings, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 432705309
Recent filing periods:
Ownership snapshot
Top reported holders of CNTN - Canton Strategic Holdings, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Highpoint Pharmaceuticals...
Disclosed value leader
Highpoint Pharmaceuticals...
Comparable rows
0/11
Latest evidence
09 Aug 2024
3/4/5
13F
Highest disclosed value: $489,028
11 rows are not safely comparable across share classes.
Showing 1-6 of 11 holder rows.
Quick read
Highpoint Pharmaceuticals LLC has the largest disclosed position value at $489K.
0 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Highpoint Pharmaceuticals LLC's linked filing trail.
Disclosed position value
Top 5
Highpoint Pharmaceuticals LLC
$489K
Kufe LLC
$407.6K
Surender Kharbanda
$362.8K
Varinder Kaur
$328.5K
Sandeep Laumas
$319.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Highpoint Pharmaceuticals LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$489,028
972,222 shares
|
— | 11 Jan 2022 |
| Kufe LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$407,629
810,395 shares
|
— | 11 Jan 2022 |
| Surender Kharbanda |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$362,784
721,240 shares
|
— | 11 Jan 2022 |
| Varinder Kaur |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$328,489
653,059 shares
|
— | 11 Jan 2022 |
| Sandeep Laumas |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$319,912
636,008 shares
|
— | 11 Jan 2022 |
| UBS Group AG |
13F
Company
|
—
denominator unverified
|
$18,250
5,170 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
24,257
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2026 Across Filers
Q2 2026 holders
68
Q3 2024 holders
4
Holder diff
-64
| Investor | Q2 2026 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend